论文部分内容阅读
目的探讨乙型肝炎病毒前C区A1896变异与患者外周血CD4+CD25+调节性T细胞水平的关系。方法应用聚合酶链反应扩增包括HBV前C区在内的DNA片段,经纯化、末端标记后测序,判读结果;应用流式细胞仪检测外周血CD4+CD25+调节性T细胞表达水平。结果68例慢性乙型肝炎(慢性乙肝)、36例肝硬化和18例肝癌患者血清A1896位碱基突变率分别为41.2%、69.4%和100.0%;A1896变异株感染者CD4+CD25+调节性T细胞水平明显低于非变异株感染者(P<0.01)。结论A1896基因变异与乙型肝炎病毒感染后肝病的慢性化及临床病情加重,CD4+CD25+调节性T细胞表达以及患者免疫状态的改变相关。
Objective To investigate the relationship between the mutation of A1896 in pre-C region of hepatitis B virus and the level of CD4 + CD25 + regulatory T cells in peripheral blood of patients. Methods DNA fragments including HBV pre-C region were amplified by polymerase chain reaction (PCR). The purified DNA fragments were sequenced and sequenced. The expression of CD4 + CD25 + regulatory T cells in peripheral blood was detected by flow cytometry. Results The nucleotide mutation rates of A1896 in 68 cases of chronic hepatitis B (chronic hepatitis B), 36 cases of cirrhosis and 18 cases of hepatocellular carcinoma were 41.2%, 69.4% and 100.0%, respectively. CD4 + CD25 + regulatory T Cell levels were significantly lower than non-mutant infected (P <0.01). Conclusion The mutation of A1896 gene is associated with chronic liver disease and worsening of clinical conditions, CD4 + CD25 + regulatory T cells and immune status in patients with hepatitis B virus infection.